The important findings from the present study are that, firstly, pharmacological activation of AMPK can improve glucose uptake in skeletal muscle cell cultures from patients with ME/CFS and secondly, cellular ATP content is significantly reduced in ME/CFS muscle cell cultures. The gene discussed is PRKAA1; the disease is myalgic encephalomeyelitis/chronic fatigue syndrome.